In Silico Clinical Trials Market Size & Analysis | Report 2021, 2028
计算机模拟试验:医疗产品创新和监管审批市场的计算建模和模拟预计将从 2021 年的 29.5765 亿美元增至 2028 年的 68.3099 亿美元;预计从 2021 年到 2028 年的复合年增长率为 12.7%。
计算机临床试验是指开发患者特定模型以形成虚拟队列,用于测试新药和医疗器械的安全性和有效性。公司使用复杂的计算建模和模拟技术在虚拟患者身上测试他们的候选药物,然后再在人体上试用。计算机建模,也称为计算机建模,允许研究人员在计算机屏幕上模拟行为。计算机
试验:医疗产品创新和监管许可的计算建模和模拟市场根据组织规模、产品、应用、临床指征、最终用户和地理位置进行细分。根据地理位置,市场大致分为北美、欧洲、亚太地区、中东和非洲以及南美和中美洲。该报告提供了对市场的见解和全面分析,强调了计算机试验:医疗产品创新和监管许可的计算建模和模拟市场规模、技术进步和市场动态等参数,以及对全球领先市场参与者的竞争格局的分析。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
计算机模拟试验:医疗产品创新和监管审批市场的计算建模和模拟:
复合年增长率(2021 - 2028 年)12.7%- 2021 年市场规模
29.6 亿美元 - 2028 年市场规模
68.3 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- InSilico Trials 技术
- 费奥普斯
- CADFEM 医疗有限公司
- 达索系统
- Virtonomy 公司
- Certara 公司
- 计算生命
- 新星
- 洞察医疗
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 中小型组织
- 大型组织
- 产品
- 平台
- 服务
- 产品设计与发现
- 产品开发
- 临床前靶向
- 药品及其他生物医药产品的评估
- 其他的
- 心血管疾病
- 神经退行性疾病
- 肿瘤学
- 罕见疾病
- 代谢疾病
- 免疫性疾病
- 传染性疾病
- 其他的
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
市场洞察
对动物福利问题的日益关注推动了计算机模拟试验:预测期内医疗产品创新和监管审批市场增长的计算建模和模拟
动物在临床试验中的快速使用主要是由于动物与人类之间的生物学相似性。动物提供了足够的人类生物学和疾病模型来提供相关信息,因此,动物模型为人类健康提供了显着的益处。然而,使用动物进行临床研究并不是药物和设备发现的唯一方式,因为几乎每一项临床研究都会以某种方式对动物及其后代造成伤害。例如,2020 年 1 月,美国农业部报告称,仅一年时间,就有约 300,000 只动物参与了引起疼痛的实验活动。
此外,善待动物组织 (PETA) 指出,每年美国实验室会杀死超过 1 亿只动物,包括老鼠、青蛙、兔子、仓鼠和豚鼠。牺牲这些动物的目的是为了生物课、医疗培训、好奇心驱动的实验以及化学、药物、食品和化妆品测试。计算机临床试验提供了一种有效的方法来替代动物解剖结构来进行各种实验和研发活动,从而支持了计算机试验市场的增长。此外,人们对动物福利的关注度迅速增加,以及人权和动物权利及福利组织的持续努力,正在推动全球计算机试验:医疗产品创新和监管许可市场增长的计算建模和模拟。
组织规模洞察
根据组织规模,全球计算机模拟试验:医疗产品创新和监管审批的计算建模和模拟市场分为小型和中型组织和大型组织。2021 年,大型组织部分占据了更大的市场份额。此外,由于大型研究组织和机构大量使用计算机模拟试验方法,预计中小型组织部分将在 2021-2028 年期间在市场上实现最高的复合年增长率。然而,在最近的时代,中型制药和生物制药公司正在采用计算机模拟模型流程来实现其试验流程并提高其创造新产品的效率。
提供见解
根据产品,全球计算机模拟试验:医疗产品创新和监管审批的计算建模和仿真市场分为产品、平台和服务。2021 年,产品部分占据了最大的市场份额。此外,服务部分预计将在 2021-2028 年期间实现市场上最高的复合年增长率。该部分增长的因素是计算机模拟试验计算建模和仿真技术中的低风险、成本效益和虚拟环境。
应用程序洞察
根据应用,全球计算机模拟试验:医疗产品创新和监管审批的计算建模和模拟市场细分为产品设计和发现、产品开发、临床前靶向、药物和其他生物医学产品评估等。2021 年,产品设计和发现部分占据了最大的市场份额。此外,预计临床前靶向部分将在 2021-2028 年期间实现市场上最高的复合年增长率。推动这一细分市场增长的因素是机器学习等先进技术的结合,人工智能被应用于药物发现和设计应用。
临床适应症见解
根据临床适应症,全球计算机模拟试验:医疗产品创新和监管审批的计算建模和模拟市场细分为心血管疾病、神经退行性疾病、肿瘤学、罕见病、代谢疾病、免疫性疾病、传染病等。2021 年,心血管疾病细分市场占据了计算机模拟试验市场的最大份额。此外,预计传染病细分市场将在 2021-2028 年期间实现最高的复合年增长率。该细分市场增长的因素是全球 COVID-19 病例的增加以及免疫系统建模在治疗该疾病方面的大力参与。
最终用户见解
根据最终用户,全球计算机模拟试验:医疗产品创新和监管审批的计算建模和模拟市场分为制药和生物制药公司、医疗技术公司、合同研究组织等。2021 年,制药和生物制药公司部门占据了计算机模拟试验市场份额的最大份额。此外,预计合同研究组织部门将在 2021-2028 年期间实现市场最高复合年增长率。
产品发布、并购和合作是全球市场参与者广泛采用的策略。以下列出了一些近期的关键市场发展:
- 2021 年 9 月,Sensyne Health 宣布推出了面向医疗保健和生命科学领域的人工智能全球数据分析平台 SENSIGHT。
- 2022 年 2 月,In SilicoTrials 宣布与 IonsGate Preclinical Services Inc (IonsGate) 合作,利用建模和模拟等创新技术。
尽管 COVID-19 疫情危机对多个行业产生了毁灭性的影响,但由于计算机辅助药物发现方法的出现,计算机模拟试验市场在此期间经历了显着增长。由于研究人员以及生物技术和生物制药公司为限制冠状病毒疾病的传播而增加研发活动,对借助计算模型进行计算机模拟试验的需求出现了更高的增长率。COVID-19 疫情的突变率不断上升,促使科学家们发现针对该疾病的有效治疗方法。因此,研究和药物发现的重要性得到了提升,从而推动了计算机模拟试验:医疗产品创新和监管许可的计算建模和模拟市场的增长。上述因素表明,疫情为市场带来了巨大的投资机会。
计算机模拟试验:医疗产品创新和监管审批市场细分的计算建模和模拟
全球计算机模拟试验:医疗产品创新和监管许可的计算建模和模拟市场根据组织规模、产品、应用、临床适应症、最终用户和地理位置进行细分。根据组织规模,计算机模拟试验:医疗产品创新和监管许可的计算建模和模拟市场分为小型和中型组织和大型组织。根据产品,计算机模拟试验:医疗产品创新和监管许可的计算建模和模拟市场分为产品、平台和服务。
根据应用,计算机模拟试验:医疗产品创新和监管审批的计算建模和模拟市场细分为产品设计和发现、产品开发、临床前定位、药物和其他生物医学产品的评估等。
根据临床适应症,计算机模拟试验:医疗产品创新和监管审批的计算建模和模拟市场细分为心血管疾病、神经退行性疾病、肿瘤学、罕见疾病、代谢疾病、免疫性疾病、传染病等。
根据最终用户,计算机模拟试验:医疗产品创新和监管审批的计算建模和模拟市场细分为制药和生物制药公司、医疗技术公司、合同研究组织等。
根据地理区域,计算机模拟试验:医疗产品创新和监管审批的计算建模和模拟市场大致分为北美、欧洲、亚太地区、中东和非洲以及南美和中美。北美市场进一步细分为美国、加拿大和墨西哥。欧洲市场细分为法国、德国、英国、西班牙、意大利和欧洲其他地区。
计算机临床试验市场报告范围
报告属性 | 细节 |
---|---|
2021 年市场规模 | 29.6亿美元 |
2028 年市场规模 | 68.3亿美元 |
全球复合年增长率(2021 - 2028) | 12.7% |
历史数据 | 2019-2020 |
预测期 | 2022-2028 |
涵盖的领域 | 按组织规模
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
亚太地区市场细分为中国、印度、日本、澳大利亚、韩国和亚太地区其他地区。中东和非洲市场进一步细分为沙特阿拉伯、阿联酋、南非和中东和非洲其他地区。南美洲和中美洲市场细分为巴西、阿根廷和南美洲和中美洲其他地区。InSilico Trials Technologies;FEops;CADFEM Medical GmbH;Dassault Systemes SE;Virtonomy GmbH;Certara Inc.;Computational Life;Novadiscovery;TwInsight Medical;Ansys, Inc.;Synopsys, Inc.;Sensyne Health plc;Phesi;Tempus;和 Cerner Corporation 是 2021 年至 2028 年预测期内在全球市场运营的领先公司之一。2020 年 5 月,总部位于英国的 Exscientia 在 C 轮融资中筹得 6000 万美元,由丹麦糖尿病药物制造商 Novo Nordisk 的全资控股公司 Novo Holdings 领投,德国药物开发公司 Evotec、美国制药公司 Bristol Myers Squibb 和亚洲私人投资伙伴 GT Healthcare Capital 参投。这使该公司的总融资额达到 1 亿美元多一点。新资本将部分用于扩展该公司在生物学领域的 AI 能力。
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market. The US is estimated to hold the largest share in the in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance accounting fastest growth of the region during the coming years.
InSilico Trials Technologies, Feops, CADFEM Medical GmbH, Dassault Systèmes, Virtonomy GmbH, Certara Inc., Computational Life, NOVA, TwInsight Medical, Ansys, Inc.; Synopsys, Inc; Sensyne Health plc, Phesi, Tempus, Cerner Corporation are among the leading companies operating in the global in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market.
The pharmaceutical and biopharmaceutical companies segment dominated the global in-silico trials: computational modelling and simulation for medical product innovation and regulatory clearance market and accounted for the largest market share in 2021.
In-silico trials refers to the development of patient-specific models to form virtual cohorts for testing the safety and/or efficacy of new drugs and medical devices. Also, with the development of computational modelling and simulation entire imaging including source, object, detection, and image interpretation components intended for R&D, optimization, technology assessment, and regulatory evaluation can be achieved.
Rising concerns over animal welfare and benefits and benefits associated with in-silico trials are the most significant factors responsible for the overall market growth.
Based on organization size, large organizations segment took the forefront lead in the worldwide market by accounting largest share in 2021 and is expected to continue to do so till the forecast period.
The List of Companies - In Silico Trials: Computational Modelling and Simulation for Medical Product Innovation and Regulatory Clearance Market
- InSilico Trials Technologies
- Feops
- CADFEM Medical GmbH
- Dassault Systèmes
- Virtonomy GmbH
- Certara Inc.
- Computational Life
- NOVA
- TwInsight Medical
- Ansys, Inc.
- Synopsys, Inc
- Sensyne Health plc
- Phesi
- Tempus
- Cerner Corporation
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.